Hospital
Brigham and Women's Faulkner Hospital, INC
Brigham and Women's Faulkner Hospital, INC was paid $45.90M by Medicaid between Jan 2018 and Dec 2024, across 405 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 11% of everything it billed.
33Billing provider infoBRIGHAM AND WOMEN'S FAULKNER HOSPITAL, INC
BOSTON, MA 02130
BOSTON, MA 02130
33aNPI1578677811assigned 08/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$45.90M
24GClaims1,319,713
24DCodes billed405
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#25 of 66
Median peer was paid$29.11M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 177,065 | $6.35M | |
| 2019 | 181,708 | $6.37M | |
| 2020 | 150,374 | $5.44M | |
| 2021 | 200,941 | $7.28M | |
| 2022 | 219,330 | $7.89M | |
| 2023 | 214,369 | $5.51M | |
| 2024incomplete | 175,926 | $7.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 13,600 | 12,097 | $5.08M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 32,652 | 30,201 | $4.75M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.8% | 25,543 | 23,848 | $3.59M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.9% | 16,155 | 14,534 | $2.71M |
| G0378 | Hospital observation service, per hour | 4.0% | 15,377 | 10,834 | $1.81M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.9% | 2,116 | 2,076 | $1.34M |
| 36902 | 2.5% | 1,115 | 1,020 | $1.15M | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 2.5% | 1,038 | 760 | $1.13M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 21,409 | 8,454 | $1.11M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.4% | 1,817 | 1,752 | $1.11M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 8,733 | 8,332 | $1.10M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2.2% | 1,393 | 1,352 | $1.02M |
393 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 9,115 | $1.01M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.7% | 1,087 | $796K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 7,105 | $781K |
| S9485 | Crisis intervention mental health services, per diem | 1.5% | 1,252 | $697K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 13,198 | $688K |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1.3% | 8,993 | $588K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 4,546 | $569K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 3,529 | $466K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,673 | $438K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,912 | $430K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,578 | $415K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,963 | $398K |
| 62323 | <1% | 1,070 | $387K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,389 | $377K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,786 | $368K |
| 96415 | <1% | 1,223 | $333K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,160 | $324K |
| J3490 | Unclassified drugs | <1% | 15,716 | $309K |
| 76830 | Ultrasound, transvaginal | <1% | 3,409 | $280K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,575 | $279K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,237 | $273K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 63,641 | $267K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,635 | $233K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,673 | $207K |
| 93971 | <1% | 1,495 | $203K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 16,157 | $199K |
| 76642 | <1% | 2,091 | $192K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,121 | $188K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,061 | $179K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,088 | $176K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 242 | $171K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,118 | $170K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 786 | $170K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 68,853 | $159K |
| 73630 | <1% | 5,320 | $157K | |
| 84484 | <1% | 16,129 | $148K | |
| 76770 | <1% | 1,155 | $147K | |
| 93017 | <1% | 2,055 | $139K | |
| 20553 | <1% | 1,284 | $138K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 997 | $136K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,190 | $132K |
| 97161 | <1% | 2,275 | $130K | |
| 97162 | <1% | 2,492 | $130K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14,599 | $128K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,494 | $125K |
| 83735 | <1% | 33,648 | $124K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,340 | $121K |
| 70496 | <1% | 789 | $121K | |
| ATP15 | <1% | 14,385 | $120K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 9,010 | $118K |
| 64493 | <1% | 250 | $118K | |
| 73030 | <1% | 3,815 | $107K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 151 | $101K |
| 83880 | <1% | 5,225 | $99K | |
| 71250 | <1% | 1,563 | $93K | |
| 73610 | <1% | 3,337 | $92K | |
| 72100 | <1% | 2,678 | $90K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,510 | $89K |
| 87631 | <1% | 1,312 | $85K | |
| ATP08 | <1% | 14,544 | $85K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 673 | $82K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 556 | $81K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 626 | $79K |
| 87590 | <1% | 4,816 | $76K | |
| 73130 | <1% | 2,887 | $76K | |
| 77080 | <1% | 1,510 | $72K | |
| 83690 | <1% | 16,931 | $71K | |
| 76536 | <1% | 715 | $71K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,387 | $69K |
| 84702 | <1% | 6,034 | $69K | |
| 87490 | <1% | 4,815 | $69K | |
| 93308 | <1% | 433 | $69K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 918 | $68K |
| 85027 | <1% | 20,536 | $68K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,967 | $67K |
| 81025 | <1% | 12,257 | $66K | |
| 81513 | <1% | 901 | $63K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,966 | $63K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,221 | $62K |
| 83605 | <1% | 8,582 | $59K | |
| 73110 | <1% | 2,129 | $58K | |
| 77062 | <1% | 599 | $57K | |
| 73562 | <1% | 2,554 | $56K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,191 | $54K |
| 83970 | <1% | 2,593 | $52K | |
| 88307 | <1% | 1,085 | $51K | |
| 80076 | <1% | 37,142 | $50K | |
| 82728 | <1% | 6,324 | $48K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,009 | $48K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 459 | $48K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 41 | $46K |
| 77065 | Tomosynthesis, mammo | <1% | 1,096 | $45K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,847 | $45K |
| 87800 | <1% | 1,386 | $42K | |
| ATP14 | <1% | 7,218 | $41K | |
| 82607 | <1% | 5,004 | $39K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 127 | $39K |
| 74183 | <1% | 239 | $38K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,908 | $37K |
| J7999 | Compounded drug, not otherwise classified | <1% | 3,368 | $33K |
| 86850 | <1% | 5,676 | $33K | |
| 73502 | <1% | 1,517 | $33K | |
| 73564 | <1% | 1,024 | $32K | |
| 82803 | <1% | 2,606 | $31K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,961 | $31K |
| 85610 | <1% | 14,370 | $30K | |
| 86803 | <1% | 3,388 | $29K | |
| 81001 | <1% | 16,843 | $29K | |
| 74246 | <1% | 168 | $29K | |
| ATP17 | <1% | 5,281 | $29K | |
| 72040 | <1% | 583 | $29K | |
| 97802 | <1% | 372 | $28K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,140 | $27K |
| 83550 | <1% | 5,294 | $26K | |
| 72141 | <1% | 152 | $25K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,375 | $24K |
| 86141 | <1% | 3,676 | $24K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,036 | $23K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,745 | $23K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,563 | $23K |
| 82746 | <1% | 2,694 | $22K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15,029 | $22K |
| 86780 | <1% | 2,242 | $22K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,119 | $21K |
| 87040 | <1% | 2,081 | $21K | |
| 80050 | General health panel | <1% | 1,419 | $21K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,061 | $21K |
| 84153 | <1% | 1,758 | $21K | |
| 87481 | <1% | 1,062 | $20K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 78 | $20K |
| 83540 | <1% | 5,454 | $20K | |
| ATP16 | <1% | 2,576 | $20K | |
| 93797 | <1% | 454 | $20K | |
| 80053 | Comprehensive metabolic panel | <1% | 19,314 | $19K |
| 85379 | <1% | 3,177 | $19K | |
| 78451 | <1% | 63 | $19K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,352 | $19K |
| 87070 | <1% | 3,282 | $18K | |
| 73080 | <1% | 753 | $18K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,320 | $18K |
| 77066 | Tomosynthesis, mammo | <1% | 977 | $18K |
| 93970 | <1% | 177 | $17K | |
| 20610 | <1% | 159 | $17K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 120 | $17K |
| 73221 | <1% | 109 | $17K | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,923 | $17K |
| 84425 | <1% | 1,163 | $17K | |
| 81003 | <1% | 13,195 | $17K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 149 | $16K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 849 | $16K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 53 | $16K |
| 86481 | <1% | 263 | $16K | |
| 84439 | <1% | 3,309 | $16K | |
| 77061 | <1% | 163 | $15K | |
| 76882 | <1% | 207 | $15K | |
| 73140 | <1% | 407 | $15K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,310 | $14K |
| 87186 | <1% | 3,036 | $13K | |
| 86900 | <1% | 6,029 | $13K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 179 | $13K |
| 71271 | <1% | 395 | $12K | |
| 87077 | <1% | 2,603 | $12K | |
| 82784 | <1% | 1,259 | $12K | |
| 86140 | <1% | 4,744 | $12K | |
| 97803 | <1% | 182 | $11K | |
| 90715 | <1% | 536 | $11K | |
| 87340 | <1% | 1,647 | $11K | |
| J9999 | Not otherwise classified, antineoplastic drugs | <1% | 714 | $11K |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,491 | $10K |
| 93975 | <1% | 126 | $10K | |
| 76775 | <1% | 129 | $10K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 188 | $10K |
| 95811 | <1% | 14 | $10K | |
| 86901 | <1% | 6,022 | $10K | |
| 80061 | Lipid panel | <1% | 13,590 | $10K |
| 83013 | <1% | 199 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 193 | $10K |
| 97116 | <1% | 247 | $10K | |
| ATP03 | <1% | 2,548 | $9K | |
| 97166 | <1% | 156 | $9K | |
| 85652 | <1% | 6,632 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,835 | $9K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,590 | $9K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,026 | $9K |
| 88342 | <1% | 2,417 | $9K | |
| ATP18 | <1% | 1,267 | $9K | |
| 80179 | <1% | 941 | $9K | |
| 70486 | <1% | 173 | $8K | |
| 84590 | <1% | 1,033 | $8K | |
| 82043 | <1% | 3,430 | $8K | |
| 64494 | <1% | 130 | $8K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,847 | $8K |
| Q0139 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis) | <1% | 23 | $8K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,987 | $8K |
| 70498 | <1% | 778 | $7K | |
| ATP11 | <1% | 1,380 | $7K | |
| 86706 | <1% | 1,018 | $7K | |
| 36905 | <1% | 17 | $7K | |
| 11104 | <1% | 12 | $7K | |
| 80143 | <1% | 866 | $6K | |
| 84100 | <1% | 8,621 | $6K | |
| 76098 | <1% | 122 | $6K | |
| ATP09 | <1% | 1,152 | $6K | |
| 88304 | <1% | 605 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 203 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 202 | $6K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,223 | $6K |
| S0013 | Esketamine, nasal spray, 1 mg | <1% | 262 | $5K |
| 70544 | <1% | 56 | $5K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,268 | $5K |
| 87641 | <1% | 248 | $5K | |
| 64615 | <1% | 74 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 40 | $5K |
| 87501 | <1% | 142 | $5K | |
| 12001 | <1% | 30 | $5K | |
| 88313 | <1% | 1,215 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,076 | $4K |
| 83883 | <1% | 445 | $4K | |
| 73590 | <1% | 123 | $4K | |
| 80299 | <1% | 324 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 391 | $4K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 856 | $4K |
| 73560 | <1% | 389 | $4K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,947 | $4K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 18,483 | $4K |
| 36215 | <1% | 31 | $3K | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 36 | $3K |
| 85730 | <1% | 666 | $3K | |
| 88360 | <1% | 39 | $3K | |
| 88312 | <1% | 908 | $3K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,059 | $3K |
| ATP23 | <1% | 316 | $3K | |
| 86038 | <1% | 394 | $3K | |
| 87640 | <1% | 256 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 27 | $3K |
| 94060 | <1% | 26 | $3K | |
| 74174 | <1% | 46 | $3K | |
| 87205 | <1% | 1,102 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 92 | $3K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 3,459 | $2K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,315 | $2K |
| 95923 | <1% | 12 | $2K | |
| 84480 | <1% | 199 | $2K | |
| 70491 | <1% | 13 | $2K | |
| 76801 | <1% | 54 | $2K | |
| 87632 | <1% | 26 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 14 | $2K |
| ATP10 | <1% | 494 | $2K | |
| 82550 | <1% | 2,351 | $2K | |
| 83655 | <1% | 157 | $2K | |
| ATP07 | <1% | 334 | $2K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 752 | $2K |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 54 | $2K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,057 | $2K |
| 85045 | <1% | 715 | $2K | |
| 86703 | <1% | 132 | $1K | |
| 80164 | <1% | 246 | $1K | |
| 84165 | <1% | 302 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,102 | $1K |
| 87400 | <1% | 237 | $1K | |
| 95924 | <1% | 12 | $1K | |
| 72131 | <1% | 47 | $1K | |
| 82962 | <1% | 12,544 | $1K | |
| 94726 | <1% | 41 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 43 | $1K |
| 94729 | <1% | 41 | $1K | |
| 84403 | <1% | 92 | $1K | |
| 83014 | <1% | 198 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 71 | $1K |
| 82565 | <1% | 1,031 | $962.96 | |
| 83520 | <1% | 70 | $945.41 | |
| 72170 | <1% | 103 | $896.57 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 54 | $869.53 |
| 86235 | <1% | 17 | $785.28 | |
| 86677 | <1% | 81 | $783.69 | |
| 83516 | <1% | 78 | $763.69 | |
| 93798 | <1% | 30 | $750.72 | |
| 84146 | <1% | 51 | $681.99 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 979 | $681.23 |
| 87184 | <1% | 227 | $671.46 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 20 | $670.81 |
| 77002 | <1% | 100 | $659.14 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 883 | $627.32 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 116 | $579.84 |
| 86787 | <1% | 50 | $550.35 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 16,705 | $544.07 |
| 88112 | <1% | 12 | $529.13 | |
| 86334 | <1% | 67 | $512.20 | |
| 82570 | <1% | 229 | $504.51 | |
| 86769 | <1% | 14 | $463.43 | |
| 73700 | <1% | 12 | $436.70 | |
| 86592 | <1% | 134 | $436.36 | |
| 74018 | <1% | 28 | $388.85 | |
| 84550 | <1% | 647 | $365.48 | |
| 87449 | <1% | 69 | $344.36 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 67 | $333.24 |
| 82010 | <1% | 57 | $326.91 | |
| ATP02 | <1% | 112 | $306.81 | |
| 86762 | <1% | 24 | $304.56 | |
| 83695 | <1% | 60 | $303.12 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 37 | $298.21 |
| 84156 | <1% | 193 | $295.87 | |
| 86704 | <1% | 39 | $292.77 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 20 | $288.09 |
| 87486 | <1% | 19 | $288.09 | |
| 87581 | <1% | 19 | $288.09 | |
| 96376 | <1% | 2,684 | $284.64 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 303 | $284.08 |
| 84132 | <1% | 698 | $282.46 | |
| 86618 | <1% | 28 | $264.96 | |
| 84145 | <1% | 630 | $244.40 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 790 | $243.25 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 189 | $230.32 |
| ATP13 | <1% | 31 | $206.91 | |
| 86431 | <1% | 50 | $191.56 | |
| 80197 | <1% | 51 | $187.95 | |
| 86160 | <1% | 13 | $185.98 | |
| 82610 | <1% | 54 | $179.63 | |
| 87338 | <1% | 13 | $170.56 | |
| 83615 | <1% | 353 | $168.79 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 4,432 | $168.74 |
| 83001 | <1% | 12 | $152.55 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 104 | $145.95 |
| 99152 | <1% | 4,283 | $137.74 | |
| 86039 | <1% | 13 | $103.50 | |
| 83721 | <1% | 37 | $102.49 | |
| 86225 | <1% | 14 | $100.32 | |
| 87324 | <1% | 16 | $98.46 | |
| 84134 | <1% | 15 | $93.17 | |
| 86376 | <1% | 12 | $92.89 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,510 | $87.65 |
| 82533 | <1% | 19 | $86.28 | |
| 87045 | <1% | 14 | $77.58 | |
| 73060 | <1% | 13 | $76.07 | |
| 83010 | <1% | 13 | $68.82 | |
| 82040 | <1% | 730 | $53.43 | |
| 89051 | <1% | 12 | $50.20 | |
| 82248 | <1% | 79 | $50.13 | |
| 83930 | <1% | 12 | $30.15 | |
| 84155 | <1% | 228 | $25.17 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 241 | $18.96 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,838 | $10.00 |
| 84460 | <1% | 634 | $5.46 | |
| 84520 | <1% | 49 | $4.07 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 75 | $2.16 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 41 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 1,100 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,035 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 403 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 339 | $0.00 |
| 76937 | 0% | 82 | $0.00 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 717 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 2,088 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 314 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 438 | $0.00 |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 16 | $0.00 |
| 84450 | 0% | 229 | $0.00 | |
| 88329 | 0% | 60 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,932 | $0.00 |
| 96367 | 0% | 13 | $0.00 | |
| 93325 | 0% | 12 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 12 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 36 | $0.00 |
| 11105 | 0% | 12 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 29 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 48 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 14 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 118 | $0.00 |
| C1769 | Guide wire | 0% | 2,479 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 1,849 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 2,531 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 179 | $0.00 |
| G2083 | Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation | 0% | 228 | $0.00 |
| C1753 | Catheter, intravascular ultrasound | 0% | 1,025 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 272 | $0.00 |
| 80320 | 0% | 251 | $0.00 | |
| 83521 | 0% | 124 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 14 | $0.00 |
| 80329 | 0% | 129 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 146 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 22 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 317 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 97 | $0.00 |
| 88142 | 0% | 45 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 99 | $0.00 |
| 75710 | 0% | 15 | $0.00 | |
| 80069 | 0% | 30 | $0.00 | |
| 88341 | 0% | 15 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 76 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 42 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 18 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHADLEY, GERARD (VP OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| ST Joseph Hospital of Nashua NH | Nashua, NH | $13.00M |
| Brigham and Women's Faulkner Hospital, INC. | Boston, MA | $138K |
| ST Joseph Hospital of Nashua NH | Milford, NH | $62K |
| ST Joseph Hospital of Nashua NH | Nashua, NH | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.